Literature DB >> 25517988

In Vitro-In Vivo Correlations Observed With Indacaterol-Based Formulations Delivered with the Breezhaler®.

Jeffry G Weers1, Andrew R Clark1, Nagaraja Rao1, Keith Ung1, Alfred Haynes1, Sanjeev K Khindri2, Sheryl A Perry2, Surendra Machineni3, Paul Colthorpe4.   

Abstract

BACKGROUND: Establishing robust in vitro-in vivo correlations (IVIVC) between aerosol performance, pharmacokinetics, and clinical efficacy is critical in developing bioequivalent drug-device combination products. Recent studies have demonstrated that realistic throat models tested under realistic test conditions may provide good IVIVC with respect to total lung deposition.
METHODS: The Alberta idealized throat (AIT) model was utilized with mean peak inspiratory flow rates determined from patient breathing studies. Various formulations of indacaterol (e.g., lactose blends, fixed dose combinations, engineered PulmoSphere™ particles) were tested in the AIT model and in clinical pharmacokinetic studies.
RESULTS: Good IVIVC were observed with respect to total lung deposition, systemic delivery, and the contribution of oral absorption to systemic delivery, with percentage differences from the mean in vivo measurements <15%, with most comparisons <5%.
CONCLUSIONS: Anatomical throat models represent an exciting tool to aid in formulation development of pharmaceutical aerosols.

Entities:  

Keywords:  Alberta Idealized Throat; IVIVC; PulmoSphere™

Mesh:

Substances:

Year:  2014        PMID: 25517988     DOI: 10.1089/jamp.2014.1178

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  5 in total

Review 1.  The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.

Authors:  Jeffry Weers; Andy Clark
Journal:  Pharm Res       Date:  2016-10-13       Impact factor: 4.200

2.  Characterization of a New High-Dose Dry Powder Inhaler (DPI) Based on a Fluidized Bed Design.

Authors:  Dale R Farkas; Michael Hindle; P Worth Longest
Journal:  Ann Biomed Eng       Date:  2015-05-19       Impact factor: 3.934

Review 3.  Bridging the Gap Between Science and Clinical Efficacy: Physiology, Imaging, and Modeling of Aerosols in the Lung.

Authors:  Chantal Darquenne; John S Fleming; Ira Katz; Andrew R Martin; Jeffry Schroeter; Omar S Usmani; Jose Venegas; Otmar Schmid
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-02-01       Impact factor: 2.849

4.  High-Efficiency Dry Powder Aerosol Delivery to Children: Review and Application of New Technologies.

Authors:  Karl Bass; Dale Farkas; Amr Hassan; Serena Bonasera; Michael Hindle; P Worth Longest
Journal:  J Aerosol Sci       Date:  2020-10-14       Impact factor: 3.433

5.  Inspiratory flow patterns with dry powder inhalers of low and medium flow resistance in patients with pulmonary arterial hypertension.

Authors:  Mariana Faria-Urbina; Keith T Ung; Laurie Lawler; Lawrence S Zisman; Aaron B Waxman
Journal:  Pulm Circ       Date:  2021-05-13       Impact factor: 3.017

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.